Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2025-08-21 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 Half-Year Report Summary' (半年度报告摘要) for 特一药业集团股份有限公司, indicating it is a summary of the company's interim financial report. It contains key financial data and operational highlights for the half-year period, such as revenue, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary derived from the full half-year report and advises investors to read the full report for comprehensive details. The length is 2858 characters, which is relatively short but contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. It is not a full Annual Report (10-K), nor a simple announcement or certification. Hence, the correct classification is IR with high confidence.
2025-08-21 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the third meeting of the sixth board of directors of 特一药业集团股份有限公司. It includes details about the board meeting, voting results, and mentions the approval of the 2025 half-year report and a special report on the management and use of raised funds. The document is short (1129 characters) and does not contain the actual half-year financial report or detailed financial statements, but rather announces the board's approval and the intention to release the half-year report on August 22, 2025. This fits the category of Board/Management Information (MANG), as it concerns board meeting resolutions and management decisions, not the full interim report itself. It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, and it is not a Report Publication Announcement (RPA) because it is focused on board resolutions rather than announcing the report's publication. Therefore, the correct classification is MANG with high confidence.
2025-08-21 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2025 年半年度财务报告" which translates to "2025 Half-Year Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2025. The report explicitly states it is unaudited and includes comprehensive financial data and analysis for the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is lengthy (15,000 characters) and contains the full financial report, not just an announcement or certification. Therefore, the correct classification is IR with high confidence.
2025-08-21 Chinese
关于使用2023年度以简易程序向特定对象发行股票部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds from a specific stock issuance in 2023 to temporarily supplement working capital. It details the amount raised, usage of funds, approvals by the board, and opinions from the sponsoring institution. The document is a formal disclosure about capital usage and financing activities related to the company's fundraising. It does not contain financial statements or comprehensive financial performance data, nor is it a report or transcript. It is clearly an update on capital/financing activities, specifically the use of proceeds from a share issuance. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it contains substantive information about the use of funds, so it is not an RPA or RNS. Confidence is high given the clear focus on fundraising and capital use.
2025-08-15 Chinese
关于使用2023年度以简易程序向特定对象发行股票部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by 特一药业集团股份有限公司 regarding the use of temporarily idle raised funds from a specific stock issuance in 2023 for cash management purposes. It details the approval by the board, the amount of funds raised, usage status, investment products, risk control measures, and the impact on the company. The document is structured as a formal disclosure to shareholders and regulatory bodies about the company's financing and capital management activities. It does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive information about the use of funds and approvals. The content fits best under the category of Capital/Financing Update (CAP), as it updates on the company's fundraising and capital usage activities, specifically the management of idle raised funds from a private placement stock issuance.
2025-08-15 Chinese
东莞证券关于特一药业使用2023年度以简易程序向特定对象发行股票部分闲置募集资金暂时补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the use of idle raised funds from a specific stock issuance by Te Yi Pharmaceutical Group Co., Ltd. It discusses the registration approval, amount raised, usage of funds, idle reasons, board approval, and compliance with regulatory rules. The document is focused on the use of funds raised through a specific capital raising event and the temporary use of idle funds to supplement working capital. It is not a full financial report, earnings release, or audit report, but rather a regulatory compliance and capital usage update related to fundraising activities. The document length is 3750 characters, which is relatively short and more of an announcement or verification opinion rather than a full report. This fits best under Capital/Financing Update (CAP) as it provides updates on fundraising and capital usage activities.
2025-08-15 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.